Calliditas Q3 outlook - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Calliditas Q3 outlook - Redeye

{newsItem.title}

Calliditas recorded Q3 product sales of SEK 125m in Q3 which is very close our and the markets expectations. The number of unique (US) subscribers has increased by >50% in Q3 and Calliditas will guide for the full year sales at the approaching Q4 report. Together with the milestone related SEK 135m income from Calliditas European partner STADA as a result of the European approval this is another strong quarter from Calliditas.

Länk till analysen i sin helhet: https://www.redeye.se/research/863065/calliditas-q3-outlook?utm_source=finwire&utm_medium=RSS

Nyheter om Calliditas Therapeutics

Läses av andra just nu

Om aktien Calliditas Therapeutics

Senaste nytt